Please login to the form below

Not currently logged in
Email:
Password:

f-star wins €15m investment

Antibody specialist f-star secures funding from existing investors and adds new members to its supervisory board

f-star, a company developing antibody-based products, has secured €15m of new financing.

The investment initiative was led by SR One, the corporate venture capital arm of GlaxoSmithKline. All of f-star's existing investors, Atlas Venture, Aescap Venture, Novo Ventures, TVM Capital, Merck Serono Ventures and MP Healthcare Venture Management, also participated in the round.

As a result of the financing SR One partner Dr Deborah Harland and Dr Axel Polack of TVM Capital will join f-star's supervisory board.

Harland said: "f-star has shown that its Modular Antibody Technology platform can generate multiple high affinity biotherapeutics against targets of varying precedence and novelty in both single- and bi-specific formats.

"We believe the platform has the potential to generate numerous novel differentiated biologics with advanced efficacy, tissue penetration and targeting capabilities compared to traditional antibodies and are excited to be part of the next stage of the company's development," she added.

13th April 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics